Effect of a new adjuvant systemic interferon alpha, 5-fluorouracil and cisplatin on advanced hepatocellular carcinoma with macroscopic portal invasion

Hepato-Gastroenterology

Volumn 55, Issue 82-83, 2008, Pages 615-620

  Imura, Satoru ^a   Ikemoto, Tetsuya ^a   Morine, Yuji ^a   Fujii, Masahiko ^a   Miyake, Hidenori ^b   Tashiro, Seiki ^c   Shimada, Mitsuo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c Shikoku Chuo Hospital   (Japan)

Author keywords

Adjuvant chemotherapy; Hepatocellular carcinoma; Interferon alpha

Indexed keywords

ALPHA INTERFERON; CISPLATIN; FLUOROURACIL; PROTEIN VP2;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FEVER; HUMAN; LIVER CELL CARCINOMA; MALE; METASTASIS; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SYSTEMIC THERAPY; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PORTAL VEIN; RETROSPECTIVE STUDIES; VASCULAR NEOPLASMS;

EID: 44349190906     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Okuda K: Early recognition of hepatocellular carcinoma: Hepatology 1986; 4:729-738.
2. Tobe T, Arii S: Improving survival after resection of hepatocellular carcinoma: Characteristics and current status of surgical treatment of primary liver cancer in Japan. Primary liver cancer in Japan. Tokyo: Springer-Verlag, 1992; pp.215-220.
3. Adachi E, Maeda T, Kajiyama K, Kinukawa N, Matsumata T, Sugimachi K, et al: Factors correlated with portal venous invasion by hepatocellular carcinoma: Univariate and multivariate analysis of 232 resected cases without pre-operative treatments. Cancer 1996; 77:2022-2031.
4. Stuart KE, Anand AJ, Jenkins RL: Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996; 77:2217-2222.
5. Fong Y, Sun RL, Jarnagin W, Blumgart LH: An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999; 29:62-67.
6. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al: Natural history of untreated non-surgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 229:790-800.
7. Okada S, Okazaki N, Nose H, Yoshimori M, Aoki K: Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology 1992; 16:112-117.
8. Ando E, Yamashita F, Tanaka M, Tanikawa K: A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997; 79:1890-1896.
9. Shimada M, Takenaka K, Kawahara N, Kajiyama K, Yamamoto K, Shirabe K, et al: Surgical treatment strategy for patients with stage IV hepatocellular carcinoma. Surgery 1996; 119:517-522.
10. Fuster J, Garcia-Valdecasas JC, Grande L, Tabet J, Bruix J, Anglada T, et al: Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series. Ann Surg 1996; 223:297-302.
11. Yamanaka N, Okamoto E, Toyosaka A, Mitunobu M, Fujihara S, Kato T, et al: Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer 1990; 65:1104-1110.
12. Liver Cancer Study Group of Japan (Eds.): General Rules for the Clinical and Pathological Study of Primary Liver Cancer. Second English Edition. Tokyo: Kanehara, 2003.
13. Ikai I, Yamaoka Y, Yamamoto Y, Ozaki N, Sakai Y, Satoh S, et al: Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy. Ann Surg 1998; 227:433-439.
14. Izumi R, Shimizu K, Ii T, Yagi M, Matsui O, Nonomura A, et al: Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 1994; 106:720-727.
15. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, et al: Combined intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94:435-442.
16. Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K: Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 1998; 55:39-47.
17. Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, et al: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-α for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88:1986-1991.
18. The Liver Cancer Study Group of Japan: Primary liver cancer in Japan. Cancer 1987; 60:1400-1411.
19. The Liver Cancer Study Group of Japan: Primary liver cancer in Japan: clinicopathological features and results of surgical treatment. Ann Surg 1990; 211:277-287.
20. The Liver Cancer Study Group of Japan: Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 1994; 74:2772-2780.
21. Furuse J, Iwasaki M, Yoshino M, Konishi M, Kawano N, Kinoshita T, et al: Hepatocellular carcinoma with portal vein tumor thrombus: embolization of arterioportal shunts. Radiology 1997; 204:787-790.
22. Chen SC, Hsieh MY, Chuang WL, Wang LY, Chang WY: Development of portal vein invasion and its outcome in hepatocellular carcinoma treated by transcatheter arterial chemo-embolization. J Gastroenterol Hepatol 1994; 9:1-6.
23. Lin DY, Lin SM, Liaw YF: Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12:S319-328.
24. Asahara T, Itamoto T, Katayama K, Nakahara H, Hino H, Yano M, et al: Hepatic resection with tumor thrombectomy for hepatocellular carcinoma with tumor thrombi in the major vasculature. Hepatogastroenterology 1999; 46:1862-1869.
25. Tanaka A, Morimoto T, Yamaoka Y: Implications of surgical treatment for advanced hepatocellular carcinoma with tumor thrombi in the portal vein. Hepatogastroenterology 1996; 43:637-643.
26. Fujii T, Takayasu K, Muramatsu Y, Moriyama N, Wakao F, Kosuge T, et al: Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol 1993; 23:105-109.
27. Tanaka A, Morimoto T, Ozaki N, Ikai I, Yamamoto Y, Tsunekawa S, et al: Extension of surgical indications for advanced hepatocellular carcinoma: is it possible to prolong life span or improve quality of life? Hepatogastroenterology 1996; 43:1172-1181.
28. Yamaoka Y, Kumada K, Ino K, Takayasu T, Shimahara Y, Mori K, et al: Liver resection for hepatocellular carcinoma (HCC) with direct removal of tumor thrombi in the main portal vein. World J Surg 1992; 16:1172-1176.
29. Sangfelt O, Erickson S, Castro J, Heiden T, Gustafsson A, Einhorn S, et al: Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 1999; 18:2798-2810.
30. Yano H, Iemura A, Haramaki M, Ogasawara S, Takayama A, Akiba J, et al: Interferon alpha receptor expression and growth inhibition by interferon alpha in human liver cancer cell lines. Hepatology 1999; 29:1708-1717.
31. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kiuchi H, et al: Integration of interferon-α/β signaling to p53 responses in tumour suppression and antiviral defence. Nature 2003; 424:516-523.
32. Horowitz RW, Heerdt BG, Hu X, Schwartz EL, Wadler S: Combination therapy with 5-fluorouracil and IFN-α2a induces a nonrandom increase in DNA fragments of less than 3 megabases in HT29 colon carcinoma cells. Clin Cancer Res 1997; 3:1317-22.
33. Sabaawy HE, Farley T, Ahmed T, Feldman E, Abraham NG: Synergistic effects of retrovirus IFN-alpha gene transfer and 5-FU on apoptosis of colon cancer cells. Acta Haematol 1999; 101:82-88.
34. Folkman J, Ingber D: Inhibition of angiogenesis. Semin Cancer Biol 1992; 3:89-96.
35. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ: Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1995; 5:2726-2734.
36. Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, et al: Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998; 58:808-814.
37. Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50:3473-3486.
38. Elias L, Sandoval JM: Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 1989; 163:867-874.
39. Schwartz EL, Hoffman M, O'Connor CJ, Wadler S: Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells. Biochem Biophys Res Commun 1992; 182:1232-1239.